Proactive Investors - Run By Investors For Investors

Synairgen says its drug well tolerated in phase II trial

Richard Marsden, CEO of Synairgen plc (LON:SNG), tells Proactive the phase II trial showed that its drug for the sufferers of chronic obstructive pulmonary disease (COPD) has been well tolerated.

 “To show the drug was well tolerated was a very important step. In coming days or weeks we will put some further data out, which hopefully will be the biomarker data,” he said.

 
Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full SNG profile View Profile

Synairgen plc Timeline

Big Picture
May 07 2019
Article
February 25 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use